Archived ASX Releases

2012 Releases

CSL Historical Financial Performance in US Dollars
In February 2012, the company announced its decision to move to US dollar reporting commencing with the 2012/13 financial year. US dollars are the pharmaceutical industry standard currency for reporting purposes. The move also reflects the increasing predominance of the Company’s worldwide sales and operations in US dollars. More.

CSL drug candidate in diabetes research breakthrough
CSL Limited has developed a new drug candidate that is able to prevent the development of type 2 diabetes and reverse its progression in animal models of the disease. More.

CSL Biotherapies awarded Pandemic Preparedness Contract by US Government
CSL Biotherapies announced that it has been awarded a contract by the United States (US) Department of Health and Human Services to supply pre-pandemic and pandemic vaccine antigens and related services to the US national stockpile. More.

Full Year Results Announcement for 2011/12
CSL Limited (ASX:CSL) today announced a net profit after tax of A$983 million for the twelve months ended 30 June 2012, up A$42 million or 4.5% on a reported basis when compared to the prior comparable period. This result included an unfavourable foreign exchange impact of A$108 million. More.

Successor to CEO Brian McNamee Announced
CSL Limited (ASX:CSL) - CSL Chairman, Professor John Shine, AO, today announced that after 23 years at the helm of CSL, Dr Brian McNamee, AO, has agreed with the Board of Directors the timing of the handover to his successor as CEO and Managing Director. More.

Retirement of Director - Peter Turner
Peter Turner, an Executive Director of CSL, will be leaving the Company as an executive and, as a consequence, retiring as a director of CSL as of 17 October 2012. More.

Half Year Results announcement for 2011/12
CSL Limited today announced its first half result for period ended 31 December 2011. More.

© 2017 CSL Limited